James M. Frates - Mar 16, 2023 Form 4/A - Amendment Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role: Chief Financial Officer
Signature: /s/ Joshua B. Cohen, as Attorney in Fact
Stock symbol: AMLX
Transactions as of: Mar 16, 2023
Transactions value $: -$812,859
Form type: 4/A - Amendment
Date filed: 3/24/2023, 06:48 PM
Date Of Original Report: Mar 20, 2023
Previous filing: Jan 10, 2023
Next filing: May 18, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMLX	Common Stock	Options Exercise	$224K	+32.5K	+95.56%	$6.88	66.5K	Mar 16, 2023	Direct	F1, F2
transaction	AMLX	Common Stock	Sale	-$981K	-30.8K	-46.3%	$31.86	35.7K	Mar 16, 2023	Direct	F1, F2, F3
transaction	AMLX	Common Stock	Sale	-$55.3K	-1.7K	-4.77%	$32.46	34K	Mar 16, 2023	Direct	F1, F2, F4
transaction	AMLX	Common Stock	Award	$0	+21.7K	+63.71%	$0.00	55.7K	Mar 16, 2023	Direct	F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMLX	Stock Option (right to buy)	Award	$0	+97.5K		$0.00	97.5K	Mar 16, 2023	Common Stock	97.5K	$32.08	Direct	F6
transaction	AMLX	Stock Option (right to buy)	Options Exercise	$0	-32.5K	-7.27%	$0.00	415K	Mar 16, 2023	Common Stock	32.5K	$6.88	Direct	F1, F2, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of 32,500 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4.
F2	These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022.
F3	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.33 to $32.30. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.33 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5	The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.
F6	1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
F7	113,024 shares underlying this option vested on January 25, 2022, with the remaining shares vesting in monthly installments of 9,416 shares thereafter.

Remarks:

Exhibit List: Exhibit 24. This signed and dated Power of Attorney is being filed to replace the Power of Attorney exhibit submitted with the Form 3 filed on January 6, 2022.